Skip to main content
Mabpharm Limited logo

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 ISIN · KYG5780F1046 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2021-09-23 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
2021 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 INTERIM REPORT' and contains detailed financial highlights, corporate information, management discussion and analysis, and interim condensed consolidated financial statements. It covers a six-month period ending June 30, 2021, which is typical for an interim or quarterly report. The presence of financial statements such as the statement of profit or loss, statement of financial position, and notes to interim condensed consolidated financial information confirms it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2021-09-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued shares, share options, and other share capital changes for the month ended 31 August 2021. The content is regulatory in nature, reporting share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report or presentation. The document is a regulatory submission related to share capital movements under exchange listing rules, fitting the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-03 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021' and contains detailed unaudited consolidated financial results for the six months ended June 30, 2021, including revenue, expenses, profit/loss, and balance sheet items. It also includes extensive business and product pipeline information, typical of a comprehensive interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is a full annual report (10-K) or an earnings release (which would be shorter and more summary-focused). The presence of detailed financial data and analysis for a half-year period aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2021-08-27 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Mabpharm Limited regarding the date of a board meeting to consider and approve the interim results for the six months ended June 30, 2021. It does not contain the interim financial report itself but rather informs about the upcoming board meeting where the interim results will be reviewed and published. The document is short (1367 characters) and serves as a notice rather than a report. According to the 'MENU VS MEAL' rule, such announcements about report publication or board meetings related to financial results are classified as Regulatory Filings (RNS) rather than the Interim Report (IR) itself.
2021-08-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, share options, and other related share capital information for Mabpharm Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules Chapter 19B. The document includes detailed tables on share capital and share options movements for the month ended 31 July 2021. It is not a full financial report, earnings release, or management discussion, but rather a regulatory filing reporting share capital movements and confirmations. The document length is 5722 characters, which is sufficient to contain substantive data rather than just an announcement. The content aligns with regulatory filings related to share capital movements rather than other categories like capital updates or director dealings. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-05 English
INSIDE INFORMATION ANNOUNCEMENT APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ON THE NEW DRUG APPLICATION (NDA) OF OUR CORE PRODUCT, CMAB008 (INFLIXIMAB FOR INJECTION)
Regulatory Filings Classification · 95% confidence The document is an announcement made by Mabpharm Limited regarding the approval of a new drug application (NDA) by the National Medical Products Administration (NMPA) in China. It is labeled as an "Inside Information Announcement" and contains detailed information about the drug, its approval, and the impact on the company. The document is a regulatory announcement about a significant corporate event (drug approval) but does not contain financial statements, management discussion, or detailed financial data. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is more than 5,000 characters and provides substantive information about the approval event. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. Therefore, the appropriate classification is RNS with high confidence.
2021-07-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.